We are live on ! Find out more
DMK

DMK Pharmaceuticals Corporation Common Stock

Delisted

DMK was delisted on the 6th of February, 2024.

52 hedge funds and large institutions have $12.1M invested in DMK Pharmaceuticals Corporation Common Stock in 2018 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 15 increasing their positions, 17 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

64% more call options, than puts

Call options by funds: $834K | Put options by funds: $508K

10% less funds holding

Funds holding: 5852 (-6)

12% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 17

32% less capital invested

Capital invested by funds: $18M → $12.1M (-$5.81M)

50% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 12

Holders
52
Holders Change
-6
Holders Change %
-10.34%
% of All Funds
1.19%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
6
Increased
15
Reduced
17
Closed
12
Calls
$834K
Puts
$508K
Net Calls
+$326K
Net Calls Change
+$559K

DMK Hedge Fund Activity: Q1 2018 in Review

52 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in DMK Pharmaceuticals Corporation Common Stock (DMK) for Q1 2018, worth a combined $12.1M — down 32% from $18M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of DMK and 6 opened new positions — a net loss of 6 holders — while 17 trimmed existing stakes and 15 added.

The largest buyer was Morgan Stanley, adding an estimated $874K. The largest seller was B. Riley Financial, exiting entirely with an estimated $1.02M sold.

  • 52 institutional investors held DMK Pharmaceuticals Corporation Common Stock (DMK) as of Q1 2018, down from 58 in Q4 2017.
  • Funds reported $12.1M of DMK Pharmaceuticals Corporation Common Stock stock for Q1 2018, down 32% quarter-over-quarter.
  • 6 funds opened new DMK Pharmaceuticals Corporation Common Stock positions in Q1 2018 and 12 closed out, a net change of -6 holders.
  • The largest DMK Pharmaceuticals Corporation Common Stock buyer in Q1 2018 was Morgan Stanley, an estimated $874K added.
  • The largest DMK Pharmaceuticals Corporation Common Stock seller in Q1 2018 was B. Riley Financial, an estimated $1.02M sold.

Based on aggregated 13F filings for Q1 2018.